Long-term outcome of retroperitoneal lymph node dissection in the management of testis cancer

Stephen D.W. Beck, Richard S. Foster

Research output: Contribution to journalReview article

19 Scopus citations


In low volume testicular cancer, (clinical stage A/B1) retroperitoneal lymph node dissection has maintained its therapeutic benefit while minimizing morbidity with the reduction of the surgical template from a full bilateral dissection to a unilateral nerve-sparring surgery. The optimal treatment for low stage disease is largely patient driven with surgery and surveillance considered the primary treatment modalities. In the post chemotherapy population, patients with complete radiographic resolution of retroperitoneal disease are observed at Indiana University as the relapse rate in this population is ∼5%. Residual masses after chemotherapy should be resected. A modified post chemotherapy dissection is adequate in low volume disease restricted to the primary landing zone of the affected testicle. In chemo-refractory disease, aggressive surgery provides a 5 year survival of 31% for patients with active cancer. Excluding chemo-naïve patients, late relapse disease is managed surgically with 50% being cured of disease.

Original languageEnglish (US)
Pages (from-to)267-272
Number of pages6
JournalWorld Journal of Urology
Issue number3
StatePublished - Aug 1 2006


  • Retroperitoneal lymph node dissection
  • Testicular cancer

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Long-term outcome of retroperitoneal lymph node dissection in the management of testis cancer'. Together they form a unique fingerprint.

  • Cite this